Which interventions offer best value for money in primary prevention of cardiovascular disease?

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Cobiac, Linda J ^a   Magnus, Anne ^b   Lim, Stephen ^c   Barendregt, Jan J ^a   Carter, Rob ^b   Vos, Theo ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MARGARINE;

ADULT; AGED; ARTICLE; AUSTRALIA; BREAD; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; EXERCISE; FEEDING BEHAVIOR; FEMALE; HEALTH CARE COST; HIGH RISK BEHAVIOR; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; SIMULATION; SODIUM RESTRICTION; STROKE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE SECTOR; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PRIMARY PREVENTION;

EID: 84864242519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041842     Document Type: Article

References (79)

1. Ford ES, Capewell S, (2011) Proportion of the Decline in Cardiovascular Mortality Disease due to Prevention Versus Treatment: Public Health Versus Clinical Care. Annual Review of Public Health 32: 5-22.
2. Unal B, Critchley JA, Capewell S, (2004) Explaining the Decline in Coronary Heart Disease Mortality in England and Wales Between 1981 and 2000. Circulation 109: 1101-1107.
3. WHO (2008) The global burden of disease: 2004 update. Geneva: World Health Organization.
4. Capewell S, Ford ES, Croft JB, Critchley JA, Greenlund KJ, et al. (2010) Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America. Bulletin of the World Health Organization 88: 120-130.
5. Unal B, Critchley JA, Capewell S, (2005) Small changes in United Kingdom cardiovascular risk factors could halve coronary heart disease mortality. Journal of Clinical Epidemiology 58: 733-740.
6. Begg S, Vos T, Barker B, Stanley L, Lopez A, (2008) Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. Medical Journal of Australia 188: 36-40.
7. Ferket BS, Colkesen EB, Visser JJ, Spronk S, Kraaijenhagen RA, et al. (2010) Systematic Review of Guidelines on Cardiovascular Risk Assessment: Which Recommendations Should Clinicians Follow for a Cardiovascular Health Check? Archives of Internal Medicine 170: 27-40.
8. Department of Health (2008) Putting prevention first- vascular checks: risk assessment and management. England: Department of Health.
9. Pennant M, Davenport C, Bayliss S, Greenheld W, Marshall T, et al. (2010) Community programs for the prevention of cardiovascular disease: a systematic review Am J Epidemiol 172: 501-516.
10. Mohan S, Campbell NRC, Willis K, (2009) Effective population-wide public health interventions to promote sodium reduction. CMAJ 181: 605-609.
11. Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, et al. (2003) Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet 361: 717-725.
12. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, et al. (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 338: b2376-.
13. Law MR, Morris JK, Wald NJ, (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. British Medical Journal 338: b1665.
14. Clarke PM, Fitzgerald EM, (2010) Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia. Medical Journal of Australia 192: 633-636.
15. Kidd J, (2006) Life after statin patent expiries. Nature Reviews Drug Discovery 5: 813-814.
16. Moon JC, Bogle RG, (2006) Switching statins. BMJ 332: 1344-1345.
17. Barnett H, Burrill P, Iheanacho I, (2010) Don't use aspirin for primary prevention of cardiovascular disease. BMJ 340: c1805.
18. Fowkes FGR, Price JF, Stewart MCW, Butcher I, Leng GC, et al. (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303: 841-848.
19. OECD (2009) Purchasing Power Parities (PPPs) for OECD Countries. Organisation for Economic Co-operation and Development.
20. Department of Health (2008) Economic modelling for vascular checks. England: Department of Health.
21. Ha DA, Chisholm D, (2010) Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam. Health Policy and Planning.
22. Rubinstein A, Colantonio L, Bardach A, Caporale J, Marti S, et al. (2010) Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. BMC Public Health 10: 627.
23. Barton P, Andronis L, Briggs A, McPherson K, Capewell S, (2011) Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. BMJ 343: d4044.
24. Cobiac LJ, Vos T, Veerman JL, (2010) Cost-effectiveness of interventions to reduce dietary salt intake. Heart 96: 1920-1925.
25. Smith-Spangler CM, Juusola JL, Enns EA, Owens DK, Garber AM, (2010) Population strategies to decrease sodium intake and the burden of cardiovascular disease. Annals of Internal Medicine 152: 481-487.
26. Beilby J, Furler J, (2005) General practitioner services in Australia. General Practice in Australia: 2004: Commonwealth of Australia pp. 128-213.
27. Department of Health and Ageing (2005) General Practice in Australia: 2004. Canberra: Commonwealth of Australia.
28. National Vascular Disease Prevention Alliance, (2009) Guidelines for the assessment of absolute cardiovascular disease risk. National Heart Foundation of Australia.
29. Anderson K, Odell P, Wilson P, Kannel W, (1991) Cardiovascular disease risk profiles. American Heart Journal 121: 293-298.
30. AIHW National hospital morbidity database Australian Institute of Health and Welfare.
31. Department of Health Western Australian Data Linkage. Department of Health (Western Australia), The University of Western Australia, Curtin University of Technolgoy, Telethon Institute of Child Health Research.
32. McElduff P, Dobson A, Jamrozik K, Hobbs M, (2000) The WHO MONICA Study, Australia, 1984-93: A summary of the Newcastle and Perth MONICA projects. Canberra: Australian Institute of Health and Welfare.
33. Thrift A, Dewey H, Macdonell R, McNeil J, Donnan G, (2000) Stroke Incidence on the east coast of Australia: The North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 31: 2087-2092.
34. Dunstan D, Zimmet P, Welborn T, Sicree R, Armstrong T, et al. (2001) Diabesity and associated disorders in Australia- 2000, The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Melbourne: International Diabetes Institute.
35. Simons L, Simons J, McManus P, Dudley J, (2000) Discontinuation rates for use of statins are high [Letter]. BMJ 321: 1084.
36. Simons LA, Ortiz M, Calcino G, (2008) Persistence with anti hypertensive medication: Australia-wide experience, 2004-2006. Medical Journal of Australia 188: 224-227.
37. PBS (2008) Pharmaceutical Benefits Schedule. Canberra: Department of Health and Ageing, Commonwealth of Australia.
38. Law MR, Wald NJ, Morris JK, Jordan RE, (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326: 1427.
39. Weng TC, Yang YHK, Lin SJ, Tai SH, (2010) A systematic review and meta-analysis on the therapeutic equivalence of statins. Journal of Clinical Pharmacy and Therapeutics 35: 139-151.
40. Senes S, Penm E, (2007) Medicines for cardiovascular health: are they used appropriately? Canberra: Australian Institute of Health and Welfare.
41. MBS (2008) Medicare Benefits Schedule. Canberra: Department of Health and Ageing, Commonwealth of Australia.
42. Food Standards Australia New Zealand, (2010) Australia New Zealand Food Standards Code. Commonwealth of Australia.
43. Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G, (2005) Meta-analysis of natural therapies for hyperlipidemia: Plant sterols and stanols versus policosanol. Pharmacotherapy 25: 171-183.
44. Ronckers ET, Groot W, Steenbakkers M, Ruland E, Ament A, (2006) Costs of the 'Hartslag Limburg' community heart health intervention. BMC Public Health 6.
45. Young L, Swinburn B, (2002) Impact of the Pick the Tick food information programme on the salt content of food in New Zealand. Health Promotion International 17: 13-19.
46. Asaria P, Chisholm D, Mathers C, Ezzati M, Beaglehole R, (2007) Chronic disease prevention: health effects and financial costs of strategies to reduce salt intake and control tobacco use. Lancet 370: 2044-2053.
47. Department of Veterens' Affairs (2008) Dietitians schedule of fees. Australian Government.
48. Department of Veterens' Affairs (2008) Exercise physiologists schedule of fees. Australian Government.
49. ABS (1995) National Nutrition Survey: Foods Eaten, Australia, 1995. Canberra: Australian Bureau of Statistics.
50. De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, et al. (2010) Cholesterol-Lowering Interventions and Stroke: Insights From a Meta-Analysis of Randomized Controlled Trials. Journal of the American College of Cardiology 55: 198-211.
51. Law MR, Wald NJ, Thompson SG, (1994) By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? British Medical Journal 308: 367-373.
52. Law MR, Frost CD, Wald NJ, (1991) By how much does dietary salt reduction lower blood-pressure? 1. Analysis of observational data among populations. British Medical Journal 302: 811-815.
53. Ezzati M, Vander Hoorn S, Rodgers A, Lopez AD, Mathers CD, et al. (2003) Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 362: 271-280.
54. Baltussen R, Adam T, Tan-Torres Edejer T, Hutubessy R, Acharya A, et al. (2003) Methods for generalized cost-effectiveness analysis. In: Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, editors. editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization.
55. Britt H, Miller G, Charles J, Henderson J, Bayram C, et al. (2009) General practice activity in Australia 1999-00 to 2008-09: 10 year data tables. Canberra: Australian Institute of Health and Welfare.
56. Begg S, Vos T, Goss J, Mann N, (2008) An alternative approach to projecting health expenditure in Australia. Australian Health Review 32: 148-155.
57. Gold MR, Stevenson D, Fryback DG, (2002) HALYs and QALYs and DALYs, oh my: Similarities and differences in summary measures of population health. Annual Review of Public Health 23: 115-134.
58. KPMG Health Education and Community Services Group (2002) Cost weight study. Melbourne, Victoria: Department of Human Services.
59. Lim S, (2005) Priority setting for the primary prevention of coronary heart disease and stroke in Australia [PhD thesis]. Melbourne: Monash University.
60. Dewey HM, Thrift AG, Mihalopoulos C, Carter R, Macdonell RAL, et al. (2001) Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 32: 2409-2416.
61. AIHW (2006) Health expenditure Australia. Canberra: Australian Institute of Health and Welfare.
62. Gold M, Siegel J, Russell L, Weinstein M, editors (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press.
63. George B, Harris A, Mitchell A, (2001) Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 19: 1103-1109.
64. AIHW (2009) Health expenditure Australia 2007-08. Canberra: Australian Institute of Health and Welfare.
65. National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010. Commonwealth of Australia.
66. PHARMAC (2010) Pharmaceutical Schedule. New Zealand: Pharmaceutical Management Agency.
67. NHS Prescription Services (2010) NHS Electronic Drug Tariff, December 2010. Department of Health, England and Wales.
68. Vos T, Carter R, Barendregt J, Mihalopoulos C, Veerman J, et al. (2010) Assessing Cost-Effectiveness in Prevention (ACE-Prevention): Final Report. University of Queensland, Brisbane and Deakin University, Melbourne.
69. Heeley E, Peiris D, Patel A, Cass A, Weekes A, et al. (2010) Cardiovascular risk perception and evidence-practice gaps in Australian general practice (the AusHEART study). Medical Journal of Australia 192: 254-259.
70. Wells S, Furness S, Rafter N, Horn E, Whittaker R, et al. (2008) Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice. European Journal of Cardiovascular Prevention and Rehabilitation 15: 173-178.
71. Antithrombotic Trialists' Collaboration, (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet 373: 1849-1860.
72. MIMS Online, (2010).
73. Pharmacy Direct, (2010).
74. Coles Online, (2010).
75. Woolworths online, (2010).
76. Brunner E, Rees K, Ward K, Burke M, Thorogood M, (2007) Dietary advice for reducing cardiovascular risk. Cochrane Database of Systematic Reviews Issue 4.
77. Ebrahim S, Beswick A, Burke M, Davey Smith G, (2006) Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews Issue 4.
78. WHO (2009) Tables of Costs and Prices used in WHO-CHOICE Analysis. CHOosing Interventions that are Cost Effective (WHO-CHOICE): World Health Organisation.
79. ABS (2009) Consumer Price Index, Australia, June quarter. Canberra: Australian Bureau of Statistics.